Research delivers insight into the B-Cell Maturation Antigen Targeted Therapies market growth by focusing on Top Key Operating Vendors like Transposagen Biopharmaceuticals, Sutro Biopharma, Malin Corporation, Eureka Therapeutics, firstVentury Equity, Five Prime Therapeutics, Credit Suisse Securities
Pune, India -- (SBWIRE) -- 03/07/2018 -- B-cell maturation antigen (BCMA) is a protein, also called tumor necrosis factor receptor superfamily member 17 (TNFRSF17) or CD269 antigen, which is encoded in humans by TNFRSF17 gene. BCMA is an essential member of tumor necrosis factor receptor super family and is preferentially expressed in B lymphocytes. B-cell maturation antigen receptor is necessary for B-cell development and also in autoimmune response. This receptor specially binds to tumor necrosis factor (TNF) super family member 13b. BCMA or TNFRSF17 binds to TNF and activates NF-kappaB and MAPK8/JNK. TNFRSF17 also binds with other TRAF family members and may conduct or transfer signals for cell proliferation and survival. It is a receptor for TALL-1, and activates NF-kappaB through a NIK-, TRAF5-, IKK-, and TRAF6- dependent pathway.
The healthcare industry recognizes medical devices as all equipment and tools that are used either individually or together for diagnostics or therapy. This spectrum includes medical instruments, materials, devices, software, and electronic devices. The competitive landscape of the global B-Cell Maturation Antigen(BCMA) Targeted Therapies market is currently hinged around the top players. Most of the players are focusing heavily on enhancement of existing technologies while still dedicating a huge chunk of their resources for product innovation. The nature of the market is such that entry for newer players can be challenging, but not impossible due to the desperate need for newer technologies and innovative patents in the market.
Get Sample Copy of this report:
The global BCMA targeted therapy market can be segmented into product type, end-user, and region. In terms of product type, the market can be segmented into CAR-T cells, bispecific antibodies, and antibody drug conjugates. These are the different kind of products related to B-cell maturation antigen based on mechanism or function perform with other proteins or cells of body as identification and destruction of tumor cell lysis of malignant multiple myeloma and conjugate formation with antibodies. In terms of end-user, the global BCMA targeted therapies market can be segmented into hospitals and cancer research institutes.
The global B-Cell Maturation Antigen(BCMA) Targeted Therapies market holds a core aspect of its demand scales on the rate of patients falling ill or suffering trauma or injuries. Of these, the accelerating spread of contagious diseases is the top factor driving the demand for medical devices. A more specific device type segment of the global market being affected by this rise is in vitro diagnostic devices. Among the number of device types categorized in the market, in vitro diagnostic devices are among the leading ones dominating the market. This is partly due to the growing demand for noninvasive diagnostic practices, of which in vitro devices form a key part of, and partly due to the significantly higher rate of improvement and advancement of technologies in this segment.
To get more information, Ask for Sample PDF illustration with TOC, Tables, Figures and Charts @
Table of Content:
Chapter 1 B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Overview
Chapter 2 Global Economic Impact on Industry
Chapter 3 Global Market Competition by Manufacturers
Chapter 4 Global Production, Revenue (Value) by Region
Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions
Chapter 6 Global Production, Revenue (Value), Price Trend by Type
Chapter 7 Global Market Analysis by Application
Chapter 8 Manufacturing Cost Analysis
Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers
Chapter 10 Marketing Strategy Analysis, Distributors/Traders
Chapter 11 Market Effect Factors Analysis
Early buyers will receive up to 40% Discount on this report